Xu Jin

Mr. Xu Jin


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2017 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PDF file
FSFang Sun
Fang Sun
QLQin Li
Qin Li
XJXu Jin
Xu Jin

26 February 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
WLWenjing Li
Wenjing Li
QZQin Zhang
Qin Zhang
HMHongjun Miao
Hongjun Miao
XJXu Jin
Xu Jin
Background: Spinal muscular atrophy (SMA) is a rare neurodegenerative disease that significantly affects multiple systems in children. Nusinersen, the first approved treatment for SMA, enhances SMN protein production by targeting the RNA splicing site of the SMN2 gene, thus improving motor function. However, the high cost of nusinersen treatment raises concerns about its economic feasibility. Methods: This study retrospectively analyzed clinical data of 42 pediatric SMA patients treated with nusinersen from January 2022 to October 2024 at our hospital. We assessed the efficacy, safety, and economic impact of nusinersen in different SMA types. Motor function was evaluated using the CHOP-INTEND, HINE-2, HFMSE, and RULM scales. Safety was assessed based on adverse reactions and events, and economic evaluation considered total treatment costs and average cost per injection. Results: Nusinersen significantly improved motor function in SMA patients, especially in type I patients, who showed notable increases in CHOP-INTEND and HINE-2 scores. The RULM score had the highest increase among type II patients, while improvements were relatively lower in type III patients. Regarding safety, the incidence of adverse events was 40.48%, with fever being the most common adverse reaction, occurring in 36.36% of cases. Economic analysis indicated that the total treatment cost was highest for type III patients, though the cost differences among types were not statistically significant (P > 0.05). Conclusion: Nusinersen demonstrated significant clinical efficacy and favorable safety in pediatric SMA patients, with improved economic feasibility after insurance coverage. Our findings support early SMA screening and presymptomatic nusinersen administration to maximize therapeutic benefits. Further multicenter, large-sample, long-term follow-up studies are warranted to validate and expand upon these findings.

5 July 2025 in Neurobiology of Disease
Verified
Journal Article
Open access
HGHong-Li Guo
Hong-Li Guo
XSXi-Li Sun
Xi-Li Sun
YXYang-Yang Xu
Yang-Yang Xu
YZYuan-Yuan Zhang
Yuan-Yuan Zhang
JWJie Wang
Jie Wang
FCFeng Chen
Feng Chen
When discussing childhood epilepsy and children's serum vitamin D status together, the matter becomes complex and intriguing. A long-standing question has been whether there is a causal link between epilepsy itself and the serum vitamin D status: does vitamin D deficiency lead to seizures, or do seizures occur alongside or result in vitamin D deficiency, or is the deficiency caused by anti-seizure medication therapy? Clarifying these questions would significantly enhance our understanding of the relationship between them and improve the treatment and management for childhood epilepsy. This narrative review summarized existing literature on vitamin D and pediatric epilepsy and collected those clinical and non-clinical researches in this field to see if sufficient evidence has accumulated to address these questions. Current evidence revealed that children with epilepsy experienced higher rates of vitamin D deficiency, but whether this stems from the condition itself or its treatment remains uncertain. Both clinical and non-clinical studies suggested vitamin D may help control seizures, but its effective dosing and treatment duration need rigorous clinical validation. This clinical situation indicates that continued attention is needed on this important clinical issue concerning children's health, as well as more efforts and attempts to ultimately clarify these matters.

30 April 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
WLWenjing Li
Wenjing Li
TDTing Ding
Ting Ding
YFYahui Feng
Yahui Feng
XJXu Jin
Xu Jin
ZLZhuo Li
Zhuo Li
Background: Asthma, a chronic respiratory disease, is a significant public health concern globally. Air pollution has been identified as one of the key risk factors exacerbating respiratory conditions, particularly in children. Previous studies have shown a correlation between air pollution levels and asthma visits. However, the impact of air pollutants on childhood asthma visits stratified by gender, age and season remains a topic of interest, and further investigation is necessary to comprehend this complex relationship.Objective: This study aimed to explore the association between air pollution and childhood asthma visits in Nanjing from 2013 to 2021. It focused on the effects of various pollutants, including PM2.5, PM10, NO2, SO2, CO, and O3, and examined variations in impact based on demographic characteristics (gender and age) and seasonal changes.Methods: Data on childhood asthma visits and concentrations of air pollutants were collected and analyzed. The lag effects of pollutants on asthma visits were assessed, and the impacts were stratified by gender, age group (0–5 years, 6–11 years, and over 11 years), and season. Statistical methods were used to identify significant correlations and the timing of maximum effects of pollutants.Results: A positive correlation was found between childhood asthma visits and concentrations of AQI, PM2.5, PM10, SO2, NO2, and CO, with the strongest effects typically occurring on lag day 1. The study revealed that PM2.5 and PM10 had a more pronounced impact on females, and children aged 0–5 years were the most affected age group. Seasonal analysis showed that PM2.5 and SO2 had the greatest impact in spring, while PM10 and NO2 were most significant in winter. Notably, SO2 showed no significant impact on childhood over 11 years old or during summer, and the negative correlation between CO concentrations and childhood asthma visits in the summer, while in other seasons, the correlation was positive.Conclusion: The findings indicate a substantial effect of air pollutants, particularly PM2.5 and SO2, on childhood asthma, emphasizing the need for targeted pollution control measures. Variations in impact based on gender, age, and season suggest the importance of tailored interventions to protect vulnerable populations, especially young children in urban and industrial areas.

1 August 2024 in Translational Pediatrics
Verified
Journal Article
Open access
PDF file
THTianjiao Hu
Tianjiao Hu
QWQizi Wu
Qizi Wu
JLJian Li
Jian Li
TLTao Li
Tao Li
XJXu Jin
Xu Jin
LZLi Zhou
Li Zhou
Background: Primary mediastinal choriocarcinoma (PCC) is a rare, highly vascular invasive, and prognostically unfavorable malignant tumor. When occurring outside the gonads, primary choriocarcinoma is commonly found in midline locations such as the mediastinum or retroperitoneum. Currently, there is no standardized treatment strategy for PCC. In the case reported herein, we employed tislelizumab and chemotherapy in the treatment of a patient with PCC, and as in March 2024, the patient remained survive. Case Description: A 15-year-old boy who presented with symptoms of fever and cough for a year. Chest computed tomography (CT) scan showed a relatively large soft tissue shadow in the right upper anterior mediastinum, measuring approximately 5.4 cm × 3.8 cm. The patient’s soft tissue exhibited unclear demarcation from surrounding mediastinal structures and was accompanied by lung metastasis. The patient underwent a fine needle aspiration biopsy for a mediastinal mass, and the pathology results indicated a germ cell tumor with solid malignant components in the mediastinum, along with pulmonary metastasis of the solid malignancy. The patient’s serum levels of beta-human chorionic gonadotropin (β-HCG) were elevated at 125,554 mIU/mL (normal range: <5 mIU/mL), and alpha-fetoprotein (AFP) was 75.8 ng/mL (normal range, 0.605–7 ng/mL). The patient’s cranial magnetic resonance imaging (MRI) plain scan indicated multiple scattered abnormal signals in both cerebral hemispheres. Subsequently, the patient was transferred to Children’s Hospital of Nanjing Medical University for his further treatment. During the treatment period, we employed various therapeutic approaches, including chemotherapy, radiotherapy and tislelizumab therapy. After five cycles of tislelizumab treatment, the patient’s symptoms of cerebral edema significantly improved, β-HCG levels decreased. Brain MRI of the patient revealed multiple abnormal signals within the skull, with some lesions showing reduction in size and significant improvement in the surrounding edema zones. The clinical symptoms of the patient improved and he achieved partial remission (PR). At the moment, the patient is living with the disease. Conclusions: The effectiveness of chemotherapy for PCC is limited. Tislelizumab may potentially serve as salvage treatment options for PCC.

29 November 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YLYao Liu
Yao Liu
HHHua He
Hua He
SZSa-Sa Zhang
Sa-Sa Zhang
JZJia Zhou
Jia Zhou
JZJinwei Zhu
Jinwei Zhu
KHKun Hao
Kun Hao
Background: Meropenem (MEM) is frequently prescribed for the empirical management of severe infections in the pediatric intensive care unit (PICU). Critically ill children exhibit substantial pharmacokinetic (PK) variability, and current dosing strategies remain inadequately evaluated, particularly in neonates, infants, and those with altered renal function. Methods: This study employed a dual modeling approach integrating population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) methodologies. Clinical data from two PICUs were utilized for PopPK model development and PBPK model evaluation. Both models were rigorously assessed using goodness-of-fit plots and prediction-based metrics. Monte Carlo simulations were subsequently conducted to calculate the probability of target attainment (PTA) for multiple dosing regimens across MICs of 0.25–16 mg/L. The pharmacodynamic target (PDT) was defined as maintaining unbound plasma concentrations above the MIC for 100% of the dosing interval (100% ƒT > MIC), and dosing regimens were considered acceptable if the PTA exceeded 90% for efficacy while avoiding potential toxicity (Css ≥ 50 mg/L). Results: A total of 202 MEM plasma concentrations from 101 pediatric patients were analyzed. Marked inter-individual variability in MEM pharmacokinetics and pharmacodynamics was observed. Augmented renal clearance (ARC) was frequently identified in PICU patients. We simultaneously developed a two-compartment population pharmacokinetic model incorporating body weight and estimated glomerular filtration rate, and a whole-body physiologically based pharmacokinetic model scaled from adults with adjustments for transporter ontogeny and renal function. The PopPK model, by incorporating interindividual variability on clearance and volume of distribution, captured a wider range of drug exposures and demonstrated superior predictive performance, particularly in subgroups with high eGFR. The PBPK model showed higher precision in the low eGFR subgroup but slightly lower overall predictive accuracy. Both models identified ARC as a key driver of subtherapeutic exposure. Standard regimens were insufficient for preterm neonates when the MIC was ≥4 mg/L, and even the maximum label-recommended dose failed to achieve the pharmacodynamic target for infants older than 1 month when the MIC was ≥2 mg/L. Conclusions: Both PBPK and PopPK frameworks reliably predicted MEM pharmacokinetics in critically ill pediatric patients, with complementary strengths across renal function strata. Model-informed simulations highlighted the inadequacy of standard dosing under conditions of ARC or elevated MIC, supporting individualized, precision-guided dosing strategies based on age, eGFR, and pathogen MIC.